Outcomes of Placing Dental Implants in Patients Taking Oral Bisphosphonates: A Review of 115 Cases

Grant, Bao Thy N.; Amenedo, Christopher; Freeman, Katherine; Kraut, Richard A.

doi:10.1016/j.joms.2007.09.019

Cited by 206 publications

(171 citation statements)

References 15 publications

Supporting

Mentioning

151

Contrasting

Unclassified

Order By: Relevance

“…[8] Duration of BP use, concomitant use of estrogen and age over 65 years can also potentiate the risk of ONJ. [9] A multicenter retrospective study22 involving 78 patients with BRONJ has reported that most patients were on intravenous BPs for oncological treatment for over a year, and had received previous treatment with chemotherapy or steroids.…”

Section: Etiopathogenesismentioning

confidence: 99%

“…It is important to distinguish and emphasize that ONJ due to orally administered BPs seems to be less frequent, less severe, and responds better to a "drug holiday" and surgical debridement.Patients receiving oral BPs seem to have a better chance of improvement with a "drug holiday". [14] The statement that the discontinuation of BP for three months prior to surgery, as recommended by the AAOMS and ADA, could either modify or not the risk of a patient developing BRONJ is controversial. The half-life of BPs is approximately 10 years, and their prolonged use results in their substantial accumulation in the skeleton.…”

Section: Diagnosismentioning

confidence: 99%

See 1 more Smart Citation

Bisphosphonate Induced Osteonecrosis of the Jaw

Tiwari¹,

Masih²,

Srivastava³

et al. 2018

AIMDR

View full text Add to dashboard Cite

Osteonecrosis of the jaw is an important but uncommon side effect of bisphosphonate therapy. It may result in disabling and sometimes disfiguring complications that may affect the quality of life of patients. It occurs more frequently in patients on intravenous nitrogen-containing forms of bisphosphonates and is thought to be time and dose dependent. Currently, there is no recognized effective treatment apart from controlling pain and accompanied infection. Prevention of this complication is therefore important. In this article, some of the key issues of bisphosphonate-associated osteonecrosis of jaw are being reviewed.

show abstract

Section: Etiopathogenesismentioning

confidence: 99%

Section: Diagnosismentioning

confidence: 99%

Bisphosphonate Induced Osteonecrosis of the Jaw

Tiwari¹,

Masih²,

Srivastava³

et al. 2018

AIMDR

View full text Add to dashboard Cite

show abstract

“…Ancak yapılan uzun dönem prospektif çalıĢmalarda, özellikle oral yolla kullanılan ve henüz tedavinin ilk üç yılında bulunan hasta grubunda uygulanan dental implantların baĢarısı, sağlıklı bireylere uygulanan dental implantların baĢarı-sından farklı bulunmamıĢtır 47 . Grant ve Fugazzotto yaptıkları retrospektif çalıĢmalarda benzer sonuçlara ulaĢmıĢlar, oral bifosfonat kullanan bireylerde dental implant cerrahisinin ilk üç yılda güvenli olduğunun altını çizmiĢlerdir 44,48 . Osteoporoz gibi kemiği direkt ilgilendiren hastalıklarda implant-kemik bağlantısını güçlendirecek özel yüzeylere sahip implantlar üretilmeye çalıĢılmıĢtır 49,50 .…”

Section: Osteoporozlu Hastalarda Dental İmplant Uygulamalarıunclassified

Osteoporoz Hastalarinda Oral Cerrahi̇ Uygulamalar

Ofluoğlu¹,

Ergün²

2015

Atatürk Üniversitesi Diş Hekimliği Fakültesi Dergisi

View full text Add to dashboard Cite

“…They reported that no osteonecrosis was noted immediately postoperatively or during follow-up period 61 patients, and all implants were functioning successfully 12 to 24 months postinsertion. Grant et al (2008) evaluated the clinical results of 115 patients who received oral BPs during implant treatment. They showed that there was no significant difference in treatment results between patients with and without oral BPs during implant treatment.…”

Section: Introductionmentioning

confidence: 99%